ArticleACS medicinal chemistry letters2018

Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.

Biao Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.